Podcasts about Alnylam Pharmaceuticals

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both companies have decided to cut at least $1 billion each from their investments, a direct response to Germany's healthcare reforms targeting reduced branded drug prices. This decision highlights how governmental policy can significantly influence pharmaceutical investment strategies, prompting companies to be more cautious in markets with strict pricing controls. Another critical area of focus is clinical trials, where ADC Therapeutics has encountered a significant challenge. The company's antibody-drug conjugate, Zynlonta, which was granted accelerated FDA approval in 2021, recently reported three times as many deaths in its study arm compared to the control group. This raises important questions about the safety profile of antibody-drug conjugates, a class of drugs celebrated for their potential in targeted cancer therapy. The situation underscores the ongoing struggle to balance efficacy with safety in innovative cancer treatments. Regulatory oversight remains a pivotal aspect of the industry. The FDA recently issued a warning letter to Medline over recurring issues with toxic bacteria in finished products, emphasizing the critical need for compliance and safety within the medical device sector. Additionally, an untitled letter was sent to QOL Medical for potentially misleading promotional communications regarding Sucraid. Such actions demonstrate the FDA's vigilance in monitoring marketing practices that could mislead healthcare providers or patients. In drug approval news, AbbVie's Qulipta and Amgen's Imdelltra have secured approvals in Europe. These milestones are part of a broader strategy by pharmaceutical companies to expand geographically and enhance product portfolios through new indications. Meanwhile, Axsome Therapeutics successfully defended its narcolepsy medication Sunosi against generic competition until 2040 by settling patent litigation with a prospective generic manufacturer. This move reflects the intense patent battles common in the industry to extend product lifecycles and maintain market exclusivity. Turning to geopolitical influences, there is heightened scrutiny on China's biotech sector following calls from U.S. lawmakers for increased oversight. The potential application of the Comprehensive Outbound Investment National Security Act to Chinese biotech investments signals escalating tensions and could significantly impact international collaborations and investments. This reflects growing concerns over intellectual property protection and biotechnological advancements within international trade dynamics. In financial developments, Parabilis Medicines is preparing for an IPO with aims to raise $476 million to fund Phase 3 trials of its desmoid tumor drug candidate. This move illustrates continued investor interest in oncology innovations despite broader economic uncertainties. On the scientific front, Autobahn Therapeutics is making strides with its thyroid hormone receptor stimulator, showing efficacy in reducing depression symptoms in bipolar disorder during Phase 2 trials. This success paves the way for pivotal trials and highlights how hormone mimics can offer new therapeutic avenues for neuropsychiatric disorders. Meanwhile, Alnylam Pharmaceuticals has entered into a groundbreaking $2 billion agreement with Inceptive Nucleics to incorporate artificial intelligence into small interfering RNA design. By leveraging AI-driven methodologies, Alnylam aims to enhance precision and efficacy in siRNA therapies, potentially speeding up drug discovery processes. Operational challenges are also evident as companies navigate complex markets like Japan, underscoring the importance of integrating regulatory and strategic planning early on to mitigate risks and ensure market feasibility. These developments paint a vivid picture of a vibrant pharmaceutical and biotech landscape where scientific innovation is rapidly advancing alongside strategic partnerships and regulatory oversight. Breakthrough technologies such as AI-driven drug design hold promise for more targeted therapies while emphasizing personalized medicine approaches. However, these advancements come with challenges like safety concerns and regulatory compliance that demand constant vigilance and adaptability from industry stakeholders. The implications for patient care are significant as these scientific breakthroughs promise new treatment avenues for complex diseases while highlighting personalized medicine approaches. As these industries continue to evolve, staying informed about scientific innovations and regulatory landscapes will be crucial for stakeholders aiming to drive future growth and improve global health outcomes. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to bring you the latest insights from around the pharmaceutical and biotech world.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VXA865. CME/AAPA credit will be available until May 15, 2027.Hidden in Plain Sight: Recognizing and Referring Patients With Transthyretin Cardiac Amyloidosis in Internal Medicine In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZCE865. CME/AAPA credit will be available until April 27, 2027.Transthyretin Cardiac Amyloidosis: Integrating New Paradigms Into Cardiology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über einen Sam Altman im Attacke-Modus, die prominenten MDax-Aufsteiger und 7 Bücher, die Euch helfen, das globale Chaos besser zu verstehen. Außerdem geht es um Alphabet, Nvidia, Tencent, Softbank, T-Mobile, Nvidia, Arm, Biogen, Lululemon, ON Semiconductor, GlobalFoundries, CDW, The Trade Desk, Alnylam Pharmaceuticals, Seagate, Western Digital, Insmed, Monolithic, Ferrovial, Meta, Tesla, Apple, Microsoft, Broadcom, T-Mobile, Applovin, Palantir, Aumovio, TKMS, Hellofresh, Gerresheimer, Teamviewer, Ottobock, Tonies, Verbio, PSI Software, LPKF, Stratec, Thyssenkrupp Nucera, Formycon, Procredit, Amadeus Fire, iShares MSCI EM SRI ETF (WKN: A2AFCZ), Xtrackers MSCI World Health Care ETF (WKN: A113FD), L&G Cyber Security ETF (WKN: A14WU5), iShares STOXX Europe 600 Construction & Materials ETF (WKN: A0H08F), iShares Core MSCI World ETF (WKN: A0RPWH), (Xtrackers MSCI Emerging Market ETF (WKN: A12GVR), Amundi Core MSCI Japan ETF (WKN: LYX0YC), iShares Core MSCI Europe ETF (WKN: A0RPWG), Xtrackers MSCI USA ETF (WKN: A1XB5V), NASDAQ-100 ETF (WKN: A0F5UF), JPMorgan US Research Enhanced ETF (WKN: A2DWM7), Xetra-Gold (WKN: A0S9GB, Euwax Gold II (WKN: EWG2LD), iShares Global Corporate Bond EUR (WKN: A1W02Q), Xtrackers II EUR Overnight Rate ETF (WKN: DBX0AN). Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships, and a focus on innovative therapies that promise to redefine patient care.One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the U.S. FDA for its ultra-long-acting biologic, Exdensur, aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options.In the oncology sector, Merck's Keytruda and Astellas Pharma's Padcev have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin-eligible muscle-invasive bladder cancer. This combination therapy of a PD-1 checkpoint inhibitor and an antibody-drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes.However, not all developments have been positive. Hansa Biopharma faced challenges with its kidney transplant drug, imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating anti-glomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases.Alnylam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA (siRNA) production. This move reflects the industry's shift towards RNA-based therapies that offer targeted gene-silencing capabilities and positions Alnylam at the forefront of RNAi therapeutics production.In another promising development, ImmunityBio reported positive data from its QUILT-3.032 study on Anktiva for BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology.The launch of Ambros Therapeutics with $125 million in Series A funding highlights efforts to develop non-opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies amidst the ongoing opioid crisis.In China, Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed-derived Alzheimer's medication. Despite skepticism over its efficacy, this investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments.Siemens Healthineers' partnership with Alzpath to incorporate pTau-217 antibodies into its Atellica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases.On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbour BioMed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies.Finally, Cencora's acquisition of OneOncology for $5 billion underscores consolidation trends within specialty practice networks. By valuing OneOncology at $7.4 billion, this acquisition reflects the growing importance of integrated oncology care models and collaborative netSupport the show

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened risk of genetic kidney conditions among South Asian populations.In this conversation, Dr Malik explains why patients of South Asian origin are more at risk of genetic kidney disease and how common these conditions are. He talks specifically about primary hyperoxaluria type 1 (PH1), the symptoms patients might present with if they have this condition - including recurrent kidney stones - and, as kidney stones are a common presentation, how healthcare professionals can recognise when these cases may warrant further investigation.This episode was presented by GPonline editor Emma Bower. It was produced by Czarina Deen.This episode of Talking General Practice has been funded by Alnylam Pharmaceuticals and produced in collaboration with GPonline. It is intended for UK healthcare professionals only.Useful linksThinkPH1.euNational Kidney Federation – PH1About Alnylam PharmaceuticalsAlnylam is a leading biopharmaceutical company and the pioneer in RNA interference (RNAi), a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam has translated the Nobel Prize-winning science of RNAi into an innovative class of medicines, with the belief that the RNAi approach to treating disease has the potential to help people around the world live longer, healthier and more fulfilling lives. Hosted on Acast. See acast.com/privacy for more information.

  In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too many women and why embedding sex- and gender-aware science from day one could accelerate fairer, more effective care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.

In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinical trial exclusion continues to skew the science. Discover why representation isn't just a workforce issue: it's a scientific necessity, and the first barrier we must dismantle to ensure better care for everyone. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.

This week, Isabel sits down with Carol Pitcher-Towner, Senior Vice President and Head of Development Programmes, Alnylam Pharmaceuticals, to unpack the gender inequities that continue to tarnish modern healthcare. Together, they explore the realities behind unequal outcomes and the steps needed to build a more inclusive future for patients. In Part 1, Carol eveals the personal experiences that made gender inequity impossible to ignore and uncovers where today's biggest gaps still exist. From disease areas where women are routinely misdiagnosed to the persistent blind spots shaping clinical practice, this episode exposes the uncomfortable truths that are still costing lives, and why fixing them can no longer be optional. Speaker bio Carol Pitcher-Towner is Senior Vice President and Head of Development Programs at Alnylam Pharmaceuticals. Since joining the company in 2014 as one of its first European regulatory leaders, she has gone on to oversee patient safety, risk management and Alnylam's global development portfolio. With more than 20 years of experience, including roles at AstraZeneca, Carol brings deep expertise across regulatory affairs and clinical development. She holds a PhD in Biological Sciences from the University of Warwick and was named an HBA Luminary in 2022 for her commitment to inclusive, patient-focused innovation. This content was reviewed by Alnylam UK Ltd for compliance with regulations applicable to the pharmaceutical industry only.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UBF865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 28, 2026.Exploring New Paradigms in Transthyretin Cardiac Amyloidosis Care: Experts vs AI In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's focus is on a series of significant advancements that are poised to reshape the landscape of drug development, regulatory standards, and patient care.Eli Lilly has made remarkable strides with its dual-action obesity medications, Zepbound and Mounjaro. Despite being removed from the CVS formulary, these drugs have achieved exceptional sales figures, reaching $10 billion in a single quarter. This success can be attributed to Lilly's innovative direct-to-consumer sales strategy, which exemplifies how modern marketing approaches can overcome traditional market barriers. Additionally, Eli Lilly's partnership with Walmart to expand access to Zepbound through retail pharmacy pickups exemplifies a strategic approach to enhancing patient access to crucial medications. By leveraging Walmart's extensive retail network, this collaboration facilitates easier access to obesity treatments—a significant public health challenge—enhancing both patient convenience and broadening market reach for Lilly's products. These achievements not only highlight the potential of strategic marketing but also underscore a growing demand for effective obesity treatments within the pharmaceutical industry.In another exciting development, Alnylam Pharmaceuticals has reported impressive sales figures for Amvuttra, a treatment for transthyretin amyloid cardiomyopathy. Surpassing analysts' expectations, this success signals a growing market for treatments targeting rare diseases and emphasizes the importance of strategic market expansion to reach underserved patient populations.Meanwhile, Bristol Myers Squibb's anticipated schizophrenia treatment, Cobenfy, has experienced a lukewarm market entry. While meeting initial expectations in its first year, it has yet to create the breakthrough impact investors anticipated. This situation highlights the challenges even well-hyped pharmaceuticals face upon launch and underscores the need for continuous strategic planning to ensure market penetration and sustained growth.A surprising development in mergers and acquisitions comes from Novo Nordisk's $6.5 billion counteroffer to acquire Metsera, an obesity biotech initially targeted by Pfizer. This aggressive move reflects intense competition in the obesity drug market and illustrates the high stakes involved in acquiring promising biotech assets that could potentially transform treatment paradigms for chronic conditions like obesity.The vaccine industry is navigating its own set of challenges with declining sales across the board. However, Merck's adult pneumococcal vaccine Capvaxive has shown promising initial sales figures. As the first pneumococcal vaccine specifically designed for adults, Capvaxive indicates a potential niche market that Merck could successfully capture.On the regulatory front, significant measures are being taken by the FDA to boost biosimilar availability against drug pricing pressures. New draft guidance aims to eliminate clinical testing requirements for biosimilars and categorize all approved biosimilars as "interchangeable." This initiative could significantly reduce biologic medicine costs post-patent expiration and increase competition in the market, potentially making essential medications more accessible to patients. Additionally, the FDA is proposing streamlined biosimilar approval pathways aimed at reducing overall bio-drug costs—a welcome move reflecting concerted efforts to make essential medications more affordable and accessible globally.Argenx has reported positive trial results for Vyvgart in treating generalized myasthenia gravis (gMG), highlighting its commitment to addressing unmet needs within this patient population. These findings could expand treatment options for gMG patients who have been previously overlooked in thSupport the show

Ken Shreve and Ed Carson analyze Tuesday's market action and discuss key stocks to watch on Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/HXH865. NCPD credit will be available until July 12, 2026.Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/HXH865. NCPD credit will be available until July 12, 2026.Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/HXH865. NCPD credit will be available until July 12, 2026.Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/HXH865. NCPD credit will be available until July 12, 2026.Nursing Strategies in Transthyretin Cardiac Amyloidosis: Targeted Therapies and the Patient Experience In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery. Chapter Summaries;00:00 Introduction to John Maraganore: Biotech Trailblazer01:11 John's Early Life and Education03:09 Joining Alnylam and the RNAi Revolution04:56 Challenges and Successes at Alnylam06:47 Current Biotech Funding Environment08:17 Global Competition and US Leadership in Biotech10:25 The Importance of In-Person Collaboration12:01 Overcoming Drug Delivery Hurdles15:21 Maintaining an Entrepreneurial Spirit in Biotech17:00 Balancing Science and Business in Decision Making20:27 Strategic Partnerships in Biotech23:36 The Role of Biotech in Global Challenges26:25 Advocating for Policy Changes in Biotech30:41 Mentoring the Next Generation of Biotech Leaders32:35 Future Frontiers in Biotech Innovation36:08 John's Vision for the Future of Biomedicine37:18 Communicating Innovation and LeadershipDon't forget to Like, Share, Subscribe, Rate, and Review! Keep up with John Maraganore;LinkedIn: https://www.linkedin.com/in/john-maraganore/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

We love to hear from our listeners. Send us a message. On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, and building therapeutic franchise "skyscrapers." Tangular also shares his thoughts on commercializing RNAi therapies for larger patient populations, compared with rare disease populations, and reflects on changes in the biopharmaceutical sales and promotion model.This episode is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.

In this insightful episode of The New CISO, host Steve Moore sits down with Sanju Misra, Chief Information Security Officer (CISO) at Alnylam Pharmaceuticals, to explore the pivotal moments that have shaped her impressive career in cybersecurity leadership. Sanju shares her strategies for navigating career transitions, the importance of aligning with a company's mission, and how to identify the right time to move on from a role.Listeners will gain valuable insights into:How Sanju built her career by embracing challenging projects and maintaining authentic professional relationships.The decision-making processes behind her moves from GE to Praxair, and eventually to Alnylam Pharmaceuticals.The evolution of her leadership style from a technical expert to a business risk executive.Why aligning with a company's culture and mission is crucial for long-term success.Tips for aspiring CISOs on taking initiative, growing their networks, and articulating risk in business terms.Sanju's reflections on imposter syndrome, professional growth, and the rewards of working in a patient-focused organization offer both inspiration and practical advice for leaders at every stage of their careers. Tune in to hear her story and discover actionable strategies for thriving as a modern CISO.0:00 - Introduction and Show Overview1:10 - Sanju Misra's Career Path: From GE to Praxair4:00 - Building Security Programs and Leadership Growth6:30 - Navigating Mergers and the Role of Culture10:00 - Transitioning from Technologist to Business Risk Leader15:50 - Career Advice for Aspiring CISOs22:00 - Key Takeaways: Communication and Leadership EvolutionLinks: LinkedIn

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

In this episode of The New CISO, host Steve Moore is joined by Sanju Misra, CISO and IT Risk Leader at Alnylam Pharmaceuticals. Sanju shares her journey from a college side hustle on a typewriter to becoming a security leader in the pharmaceutical industry. Along the way, she reflects on the importance of taking risks, embracing roles outside of your comfort zone, and the power of transferable skills.Listen to Steve and Sanju discuss career transitions, building diverse teams, and why not checking every box on a job description might be the best career move:00:00 - Meet Sanju06:15 - The Start of a Tech Journey18:30 - Taking the Leap27:00 - Advice for Job Seekers39:45 - Hiring from Within51:15 - Networking and Career GrowthLinks: LinkedIn

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/questions-and-answers-on-amyloid-cardiomyopathy-and-polyneuropathy-9845SummaryIn this activity – which learners can review as a podcast or a webcast - Drs. Chafic Karam and Michelle Kittleson dive into five key questions from recent live-virtual broadcasts about transthyretin amyloidosis (ATTR). They discuss the role of cardiac MRI, biopsy, and genetic testing in diagnosing ATTR cardiomyopathy and polyneuropathy. They also explore treatment options, including silencing therapies and stabilizers, with insights into when patients should be referred for specialized care. The conversation emphasizes the importance of early diagnosis, collaborative care between neurologists and cardiologists, and the expanding therapeutic landscape for ATTR.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Describe the correct diagnostic algorithm for suspected ATTR, including interpretation of the monoclonal protein screen and indications for biopsy and genetic testing.Initiate appropriate management, including disease-directed therapy and appropriate cardiac care, or referral when indicated.This activity is accredited for CME/CE CreditAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).In support of improving patient care, this activity has been planned and implemented by Haymarket Medical Education (HME) and NACE. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.This knowledge-based activity JA4008232-9999-24-043-H01-P qualifies for 0.25 contact hours (0.025 CEUs) of continuing pharmacy education credits.For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc., and an educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

This episode is a discussion of the paper entitled, "Catheter Ablation versus Advanced Therapy for Patients with Severe Heart Failure and Ventricular Electrical Storm." https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.hrthm.2024.09.045 Host Disclosure(s): W.Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): R. Kerley: Nothing to disclose. A. Desai: Research: Novartis, Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Honoraria/Speaking/Consulting: Novartis, Abbott, AstraZeneca, Regerneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceutricals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlacoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal, Membership on Advisory Committees: BioFourmis

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EZY865. CME credit will be available until October 9, 2025.Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EZY865. CME credit will be available until October 9, 2025.Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Discover the cutting-edge world of RNA interference (RNAi) therapeutics with Dr. Akshay Vaishnaw, Chief Innovation Officer at Alnylam Pharmaceuticals. In this episode, Dr. Vaishnaw sheds light on the groundbreaking concept of RNAi therapeutics, offering a powerful new approach to treating a wide range of diseases. Learn how Alnylam Pharmaceuticals is revolutionizing healthcare with its unwavering commitment to innovation, despite facing numerous setbacks and challenges along the way.

Scott Wapner and the Investment Committee discuss whether the rally can last as we approach the second half of the year. The calls of the day include Chipotle, UnitedHealth, and Nike. The experts debate the energy trade. The chart of the day is Alnylam Pharmaceuticals.Investment Committee Disclosures